

HYPOGLYCEMICS, ALPHA-GLUCOSIDASE INHIBITORS PRIOR AUTHORIZATION FORM

- Please submit all requested documentation with this form. Incomplete documentation may delay the processing of this request.
- Prior authorization guidelines for **Hypoglycemics, Alpha-Glucosidase Inhibitors** and **Quantity Limits/Daily Dose Limits** are available on the Pharmacy Services website at <http://www.dhs.pa.gov/provider/pharmacyservices/drugsrequiringclinicalpriorauthorization>.

PRIOR AUTHORIZATION INFORMATION		PRESCRIBER INFORMATION	
<input type="checkbox"/> New request	<input type="checkbox"/> Renewal request	total # of pages: _____	Prescriber name:
Name of office contact:		Specialty:	
Contact's phone number:		State license #:	
LTC facility contact/phone:	NPI:	MA Provider ID#:	
RECIPIENT INFORMATION		Street address:	
Recipient Name:		Suite #:	City/state/zip:
Recipient ID#:	DOB:	Phone:	Fax:

CLINICAL INFORMATION

Non-preferred medication requested:			
		<input type="checkbox"/> miglitol tablet	<input type="checkbox"/> Precose tablet
Strength:	Dose/directions:	Quantity:	Refills:
Diagnosis (<i>submit documentation</i>):		DX code (<i>required</i>):	
1. Does the Recipient have a history of trial and failure, contraindication, or intolerance of the preferred Hypoglycemics, Alpha-Glucosidase Inhibitors? <i>Check all that apply.</i> <input type="checkbox"/> acarbose tablet <input type="checkbox"/> Glyset tablet		<input type="checkbox"/> Yes – <i>Submit all supporting documentation of preferred agents tried and treatment outcomes, including contraindications or intolerances.</i> <input type="checkbox"/> No	

PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION TO DHS – PHARMACY DIVISION

Prescriber Signature:	Date:
------------------------------	--------------

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.